Journey Medical Announces 85% Access to Emrosi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy DERM?
Journey Medical announced that approximately 85% of all commercial lives in the United States now have access to Emrosi after contracting with the third major group purchasing organization, GPO. Emrosi is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi, with expanded payer access anticipated to facilitate further growth in total prescription demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DERM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DERM
Wall Street analysts forecast DERM stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.000
Low
13.00
Averages
14.00
High
16.00
Current: 5.000
Low
13.00
Averages
14.00
High
16.00
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Journey Medical Corporation for potential securities fraud by its executives, which could undermine investor confidence and lead to stock price volatility.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and co-pay assistance programs, indicating potential growth in the market.
- Significant Stock Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, reflecting market concerns about the company's financial health.
- Management Acknowledgment: The management acknowledged that some prescriptions were not reimbursed, impacting the co-pay assistance program, while stating that gross-to-net performance remained in line with expectations, demonstrating the company's efforts to navigate market challenges.
See More
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Journey Medical Corporation has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for more information, highlighting concerns over corporate governance and compliance.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and the use of co-pay assistance programs, reflecting the complex dynamics between market demand and revenue.
- Significant Stock Price Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, indicating market concerns regarding the company's financial health.
- Management Acknowledgment: Journey's management acknowledged that a portion of prescriptions were not reimbursed, impacting the co-pay assistance program, while stating that gross-to-net performance remained in line with expectations, indicating ongoing adjustments in the company's strategy to address market challenges.
See More
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Journey Medical Corporation has engaged in securities fraud or other unlawful business practices, prompting investors to seek legal counsel, which raises serious concerns about corporate governance.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and co-pay assistance programs, indicating potential issues in revenue recognition.
- Significant Stock Price Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, reflecting market concerns regarding the company's financial health.
- Management's Statement: Management acknowledged that a portion of prescriptions were not reimbursed, impacting the co-pay assistance program, and while they stated gross-to-net performance was in line with expectations, this did not alleviate investor concerns, potentially leading to further market volatility.
See More
Journey Medical Expands Emrosi™ Access to 85% of U.S. Lives
- Market Access Expansion: Journey Medical has secured contracts with the third major group purchasing organization, enabling approximately 85% of commercial lives in the U.S. to access Emrosi™, significantly enhancing market penetration and driving sales growth.
- Increased Prescription Demand: The launch of Emrosi™ is expected to further boost prescription demand, as Journey Medical focuses on delivering cost-effective dermatological therapies aimed at improving patient access and satisfaction.
- Long-term Value Creation: The company plans to continue promoting formulary adoption throughout 2026 and beyond, aiming to establish Emrosi™ as the standard of care for rosacea, thereby generating sustained commercial growth.
- Significant Patient Impact: According to the National Rosacea Society, over 17 million Americans are affected by rosacea, and Journey Medical's initiatives are set to improve the quality of life for these patients, reducing social barriers caused by their condition.
See More
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
See More
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
See More
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Journey Medical Corporation for potential securities fraud by its executives, which could undermine investor confidence and lead to stock price volatility.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and co-pay assistance programs, indicating potential growth in the market.
- Significant Stock Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, reflecting market concerns about the company's financial health.
- Management Acknowledgment: The management acknowledged that some prescriptions were not reimbursed, impacting the co-pay assistance program, while stating that gross-to-net performance remained in line with expectations, demonstrating the company's efforts to navigate market challenges.
See More
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Journey Medical Corporation has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for more information, highlighting concerns over corporate governance and compliance.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and the use of co-pay assistance programs, reflecting the complex dynamics between market demand and revenue.
- Significant Stock Price Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, indicating market concerns regarding the company's financial health.
- Management Acknowledgment: Journey's management acknowledged that a portion of prescriptions were not reimbursed, impacting the co-pay assistance program, while stating that gross-to-net performance remained in line with expectations, indicating ongoing adjustments in the company's strategy to address market challenges.
See More
Journey Medical Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Journey Medical Corporation has engaged in securities fraud or other unlawful business practices, prompting investors to seek legal counsel, which raises serious concerns about corporate governance.
- Financial Results Disclosure: On March 25, 2026, Journey reported that prescription demand for Emrosi exceeded reported revenue, partly due to reimbursement timing and co-pay assistance programs, indicating potential issues in revenue recognition.
- Significant Stock Price Drop: Following the earnings report, Journey's stock price fell by $2.05, or 30.01%, closing at $4.78 per share on March 26, 2026, reflecting market concerns regarding the company's financial health.
- Management's Statement: Management acknowledged that a portion of prescriptions were not reimbursed, impacting the co-pay assistance program, and while they stated gross-to-net performance was in line with expectations, this did not alleviate investor concerns, potentially leading to further market volatility.
See More
Journey Medical Expands Emrosi™ Access to 85% of U.S. Lives
- Market Access Expansion: Journey Medical has secured contracts with the third major group purchasing organization, enabling approximately 85% of commercial lives in the U.S. to access Emrosi™, significantly enhancing market penetration and driving sales growth.
- Increased Prescription Demand: The launch of Emrosi™ is expected to further boost prescription demand, as Journey Medical focuses on delivering cost-effective dermatological therapies aimed at improving patient access and satisfaction.
- Long-term Value Creation: The company plans to continue promoting formulary adoption throughout 2026 and beyond, aiming to establish Emrosi™ as the standard of care for rosacea, thereby generating sustained commercial growth.
- Significant Patient Impact: According to the National Rosacea Society, over 17 million Americans are affected by rosacea, and Journey Medical's initiatives are set to improve the quality of life for these patients, reducing social barriers caused by their condition.
See More
Journey Medical Corporation Reports Strong Q4 2025 Earnings with Emrosi Launch Success
- Emrosi Sales Surge: Journey Medical's oral rosacea treatment, Emrosi, launched in 2025, achieved $14.7 million in net sales since its release, indicating strong market demand and effective promotional strategies, which are expected to further drive revenue growth.
- Improved Financial Performance: The company reported total revenues of $61.9 million for 2025, reflecting a 10% increase, with gross margin rising to 66.2%, demonstrating solid profitability and growth potential despite competitive pressures on legacy products.
- Prescription Volume Increase: Emrosi's prescription volume surged nearly 50% sequentially in Q4 2025, with over 3,500 unique dermatology prescribers writing at least one script, indicating significant market acceptance and trust among physicians.
- Optimistic Future Outlook: Management expects to maintain positive adjusted EBITDA in 2026 and plans to launch one or two incremental dermatology products, showcasing a proactive strategic approach to expanding product lines and market share.
See More
Journey Medical Reports FY 2025 Financial Results with Mixed Performance
- Revenue Growth: Journey Medical reported FY 2025 revenue of $61.6 million, reflecting a 9.7% year-over-year increase, although it missed analyst expectations by $3.05 million, indicating volatility in market demand.
- Gross Margin Improvement: The gross margin for FY 2025 improved to 66.2% from 62.8% in FY 2024, driven by increased sales of higher-margin products like Emrosi™ and Qbrexza®, showcasing the company's success in optimizing its product mix.
- Increase in SG&A Expenses: Selling, general, and administrative expenses rose to $44.4 million in FY 2025, a 10% increase from $40.2 million in FY 2024, primarily due to incremental operational activities related to the launch and commercialization of Emrosi™, which may impact future profitability.
- Reduction in Net Loss: The net loss for FY 2025 was $11.4 million, or $0.47 per share, an improvement from a net loss of $14.7 million, or $0.72 per share in FY 2024, indicating the company's efforts in cost control and efficiency enhancement.
See More
